The Invicta Diagnostic IPO was subscribed overall 4.27 times on the last day, while the retail quota was subscribed 3.44 times, the QIB quota was subscribed 3.51 times, and the NII quota was subscribed 6.96 times, respectively.
Invicta Diagnostic IPO Details
Invicta Diagnostic has received approval from SEBI for its IPO of ₹28.12 crores, comprising a fresh issue of ₹28.12 crores with a face value of ₹10 each. It has a set price band of ₹80 to ₹85 per share.
Invicta Diagnostic Funds Utilisations
- A portion of IPO money would be used towards funding capital expenditure for the purchase of medical equipment towards the establishment of five new diagnostic centres in Maharashtra.
- A portion of IPO money is used for the General Corporate Purpose.
Invicta Diagnostic Shares Distributions
Moreover, the retail category had 3200 shares in a 2-lot size with a minimum application and a maximum category.
S-HNI got 4800 shares in 3 lot sizes for the minimum category.
S-HNI got 11,200 shares in 7 lot sizes.
S-HNI got 12,800 shares in 8 lot sizes.
To participate in this IPO, each investor group has a tailored investment range.
- Retail Minimum and Maximum Application:- ₹2,72,000.
- S-HNI Minimum Application:- ₹4,08,000.
- S-HNI Maximum application:- ₹9,52,000.
- B-HNI Minimum application: ₹10,88,000.
Invicta Diagnostic Subscription Duration
Started on December 1, 2025, and closed on December 3, 2025. The allotment was on December 4, 2025, and non-allottees got a refund on December 5, 2025. The Invicta Diagnostic IPO listing is today, December 8, 2025.
About Invicta Diagnostic IPO
Invicta Diagnostic Limited has been engaged in providing radiology and pathology solutions since January 2021. Under the brand ‘PC Diagnostics’, the company provides pathology and radiology tests, including imaging and teleradiology. Invicta runs 7 diagnostic centres and a central lab across Mumbai, Maharashtra. As of October 31, 2025, the company provides a wide range of medical specialty tests, including 60 routine and 487 specialized pathology tests, along with 96 basic and 130 advanced radiology tests.
The company offers a wide range of pathology and radiology tests, including biochemistry and clinical pathology, cytogenetics, high-end molecular diagnostics, basic echocardiograms, X-rays, ultrasounds, CT scans, MRI scans, and PET/CT scans. Moreover, the company also runs a hub-and-spoke model in the Mumbai Metropolitan Region with a main hub in Thane West, 3 additional hubs in Bhayandar, Byculla, and Marol, and 3 spokes in Lower Parel, Sewri, and Kalwa.
